A drug from Mirati Therapeutics designed to block the cancer protein called KRAS shrank tumors in 22% of patients with advanced colon cancer, according to results from a clinical trial presented Sunday.
When the Mirati drug, a pill called adagrasib, was combined with another targeted medicine, the colon cancer response increased to 43%.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
